Comparison 5. Chemotherapy with irinotecan versus non‐irinotecan‐containing regimes.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Overall survival	10	2135	Hazard Ratio (Fixed, 95% CI)	0.87 [0.80, 0.95]
1.1 Substitutive comparisons	6	826	Hazard Ratio (Fixed, 95% CI)	0.87 [0.75, 1.00]
1.2 Additive comparisons	3	500	Hazard Ratio (Fixed, 95% CI)	0.88 [0.76, 1.03]
1.3 Other comparisons	2	809	Hazard Ratio (Fixed, 95% CI)	0.87 [0.76, 1.00]
2 Tumour response	10	1266	Odds Ratio (M‐H, Random, 95% CI)	1.72 [1.24, 2.40]
2.1 Substitutive comparisons	6	756	Odds Ratio (M‐H, Random, 95% CI)	1.53 [0.93, 2.50]
2.2 Additive comparisons	3	345	Odds Ratio (M‐H, Random, 95% CI)	2.18 [1.25, 3.80]
2.3 Other Comparisons	2	165	Odds Ratio (M‐H, Random, 95% CI)	1.87 [0.89, 3.91]
3 Progression‐free survival	7	1640	Hazard Ratio (Fixed, 95% CI)	0.76 [0.69, 0.84]
3.1 Substitutive comparison	5	741	Hazard Ratio (Fixed, 95% CI)	0.85 [0.72, 1.00]
3.2 Additive comparisons	1	90	Hazard Ratio (Fixed, 95% CI)	0.51 [0.33, 0.77]
3.3 Other comparisons	2	809	Hazard Ratio (Fixed, 95% CI)	0.74 [0.66, 0.84]
4 Treatment‐related death	9	1979	Odds Ratio (M‐H, Random, 95% CI)	0.88 [0.23, 3.32]
5 Treatment discontinuation due to toxicity	9	1979	Odds Ratio (M‐H, Random, 95% CI)	1.00 [0.46, 2.20]